Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years the day of inclusion~* Mechanical ventilation through an endotracheal tube for more than three consecutive days (72h)~* Written informed consent of the patient or a proxy~* Patients covered by or having the rights to French social security~* Negative pregnancy test, at the time of inclusion, in women of childbearing potential~Exclusion Criteria:~* Suspicion or confirmed VAP the day of inclusion~* Clinical indication for systemic aminoglycoside therapy the day of inclusion : as deemed necessary by the clinician in charge~* Stage 2 or 3 KDIGO\* classification acute kidney injury the day of inclusion excepted in patients undergoing renal replacement therapy~* Chronic kidney failure : baseline glomerular filtration lower than 30 mL/min~* Patient scheduled for extubation within the next 24h~* Patient ventilated through an endotracheal tube for more than four consecutive days before inclusion (96h)~* Patient ventilated through a tracheostomy~* Patients allergic to aminoglycosides~* Myasthenia gravis~* Known pregnant women at the time of inclusion and lactating patients~* Known guardianship or trusteeship at the time of inclusion~* Patients previously included in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhaled amikacin (Type: EXPERIMENTAL): Inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
- Placebo (Type: PLACEBO_COMPARATOR): Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.

Based on this trial design, predict the completion outcome and termination type (if applicable).